#atrial-fibrillation #left-atrial-appendage-closure #catheter-ablation #stroke-prevention #bleeding-prevention

Left Atrial Appendage Closure after Ablation for Atrial Fibrillation (OPTION Trial)

Authors, Journal, Affiliations, Type, DOI

Oussama M. Wazni, Walid I. Saliba, Devi G. Nair, Eloi Marijon, Boris Schmidt, and the OPTION Trial Investigators
New England Journal of Medicine 2025;392:1277-87 (published online November 16, 2024; print April 3, 2025)
Principal investigator: Cleveland Clinic; 106 sites, 10 countries
Type: International multicenter open-label randomized controlled trial; funded by Boston Scientific (Watchman FLX manufacturer); independent clinical events committee; core lab blinded to group assignment
DOI: 10.1056/NEJMoa2408308

Overview

The OPTION trial randomized 1,600 AF patients with elevated stroke risk (CHA₂DS₂-VASc ≥2 men / ≥3 women) who underwent catheter ablation to LAAO (Watchman FLX) or OAC, with 36-month follow-up. LAAO was superior for non-procedure-related bleeding (8.5% vs 18.1%; HR 0.44) and noninferior for the composite of death/stroke/SE (5.3% vs 5.8%). This is the first large RCT establishing LAAO as a mechanically safe and bleeding-sparing alternative to indefinite anticoagulation specifically in the post-ablation AF population, against a contemporary DOAC-predominant comparator (95% NOAC).

Keywords

Left atrial appendage closure, atrial fibrillation ablation, oral anticoagulation, stroke prevention, bleeding, Watchman FLX, OPTION trial, CHA₂DS₂-VASc, catheter ablation

Key Takeaways

Background and Rationale

Current guidelines mandate indefinite OAC after AF ablation for moderate-to-high stroke risk patients regardless of perceived ablation success, due to risk of asymptomatic AF recurrence
OAC has significant limitations: ~25% of patients stop within 1 year due to bleeding, patient anxiety, and cost
Prior LAAO RCTs (PROTECT AF, PREVAIL) compared primarily to warfarin, and PRAGUE-17 (small n) vs NOACs; a large post-ablation-specific trial was absent
The OPTION trial was designed to test whether LAAO can safely reduce bleeding burden while maintaining stroke protection after ablation

Methods

1,600 patients randomized 1:1; randomization stratified by site and timing of ablation
Ablation performed before device implant; timing: 90–180 days before randomization (sequential) or within 10 days after (concomitant; 40.9% of patients)
Ablation modalities: radiofrequency 59.4%, cryoablation 33.2%; sinus rhythm restored post-ablation: 88.1%
OAC group: 95% received NOAC (apixaban 59.3%, rivaroxaban 27.2%, edoxaban 4.3%, dabigatran 3.9%); 84.8% continued OAC throughout trial
Post-LAAO protocol: OAC + aspirin for 90 days → aspirin alone until 12 months; only 10.1% of device group remained on OAC at 36 months
Imaging (TEE recommended or CT) at 3 and 12 months post-implant
Mean age 69.6±7.7 years; 34.1% women; mean CHA₂DS₂-VASc 3.5±1.3; HAS-BLED 1.2±0.8

Non-procedure-related major or CRNM bleeding at 36 months: 8.5% (LAAO) vs 18.1% (OAC); HR 0.44 (95% CI 0.33–0.59); P<0.001 for superiority
56% relative risk reduction in non-procedure-related bleeding with LAAO
Benefit driven largely by reduction in clinically relevant nonmajor bleeding (medical intervention, hospitalisation, face-to-face evaluation required)
Result consistent in per-protocol and on-treatment sensitivity analyses
The 18.1% bleeding rate in OAC group was high despite relatively low HAS-BLED of 1.2, emphasising the challenge of long-term DOAC therapy

Primary Efficacy Endpoint — Composite Death/Stroke/SE (Noninferiority)

Death from any cause, stroke, or systemic embolism at 36 months: 5.3% (LAAO) vs 5.8% (OAC); HR 0.91 (95% CI 0.59–1.39); one-sided 97.5% upper CL 1.8; P<0.001 for noninferiority; difference −0.5 percentage points
Noninferiority margin: 5 percentage points (relative risk 1.5) — consistent with prior LAAO NI trials
All-cause death: 3.8% LAAO vs 4.5% OAC; no device-related deaths
Ischemic stroke: 1.2% LAAO vs 1.3% OAC (very low in both arms)
Hemorrhagic stroke: 0.4% in each group
Systemic embolism: 0.3% LAAO vs 0.1% OAC

ISTH major bleeding (including procedure-related) at 36 months: 3.9% LAAO vs 5.0% OAC; HR 0.77 (95% CI 0.48–1.24); NI met (P<0.001); superiority not met (P=0.28)
Even with procedure-related events included, major bleeding was numerically lower with LAAO

Device Performance

Implantation success: 98.8% (753/762 attempts)
Complete seal at 3 months: 81.0%; at 12 months: 79.7%
Device-related thrombus at 12 months: 1.9%
Pericardial effusion requiring intervention: 0.3% device vs 0.7% OAC
Device/procedure complications: 22 patients (device group) + 1 crossover patient = 23 total
82 anticoagulation-group patients crossed over to device (67% after primary endpoint event)
Note: CT used in 16% of patients at 12 months; lower complete seal rate vs PINNACLE FLX (79.7% vs 90%) likely reflects CT's greater sensitivity for small leaks vs TEE

AF Recurrence Context

Recurrence of atrial arrhythmia similar between groups; outcome differences unlikely attributable to differential AF burden reduction
Low stroke rates in both arms consistent with post-ablation reduction in AF burden

Limitations of the Document

Funded by Boston Scientific (device manufacturer); confidentiality restrictions between sponsor and authors between data availability and publication
Open-label design: anticoagulation group patients may have sought medical attention more frequently for minor bleeding, potentially inflating CRNM bleeding rate in OAC arm
Pulsed-field ablation (PFA) not available at time of trial (2019–2021); energy source choice unlikely to alter stroke prevention strategy post-ablation
Patients with LVEF ≤30% excluded; results not applicable to this population
No imputation for missing data; crossover rate in OAC group was 10.3% (82 patients), predominantly post-endpoint event — may underestimate true LAAO benefit
36-month follow-up; longer-term durability of LAAO vs ongoing OAC unknown
20% of device group had incomplete LAA seal at 12 months; clinical significance of residual peridevice leaks ≤3 mm uncertain

Key Concepts Mentioned

concepts/Catheter-Ablation-AF — trial population; LAAO as post-ablation OAC alternative
concepts/AF-CARE — "Avoid stroke" pillar; LAAO in post-ablation context
concepts/CHA2DS2-VA — stroke risk stratification tool; trial eligibility criterion

Key Entities Mentioned

entities/LAAO — Watchman FLX device; OPTION trial results; NI + bleeding superiority
entities/Atrial-Fibrillation — primary indication; post-ablation stroke prevention management

Wiki Pages Updated

wiki/sources/laao-option-nejm-2025.md — created (this file)
wiki/entities/LAAO.md — OPTION trial expanded in landmark table; key facts updated; source added
wiki/concepts/Catheter-Ablation-AF.md — OPTION trial added to anticoagulation post-ablation section; source added
wiki/sourceindex.md — new entry added
wiki/wikiindex.md — LAAO and Atrial-Fibrillation entries updated